Cargando…
Elevated Levels of the Anti-Inflammatory Interleukin-1 Receptor Antagonist Precede the Onset of Type 2 Diabetes: The Whitehall II Study
OBJECTIVE—Interleukin-1 receptor antagonist (IL-1Ra), a natural inhibitor of interleukin-1β, has been shown to improve β-cell function and glycemic control in patients with type 2 diabetes. The aim of this study was to investigate whether baseline systemic levels of IL-1Ra are associated with incide...
Autores principales: | Herder, Christian, Brunner, Eric J., Rathmann, Wolfgang, Strassburger, Klaus, Tabák, Adam G., Schloot, Nanette C., Witte, Daniel R. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2646020/ https://www.ncbi.nlm.nih.gov/pubmed/19073760 http://dx.doi.org/10.2337/dc08-1161 |
Ejemplares similares
-
Change in Sleep Duration and Type 2 Diabetes: The Whitehall II Study
por: Ferrie, Jane E., et al.
Publicado: (2015) -
Accelerated Increase in Serum Interleukin-1 Receptor Antagonist Starts 6 Years Before Diagnosis of Type 2 Diabetes: Whitehall II Prospective Cohort Study
por: Carstensen, Maren, et al.
Publicado: (2010) -
Dietary Patterns, Insulin Resistance, and Incidence of Type 2 Diabetes in the Whitehall II Study
por: McNaughton, Sarah A., et al.
Publicado: (2008) -
The Systemic Immune Network in Recent Onset Type 1 Diabetes: Central Role of Interleukin-1 Receptor Antagonist (DIATOR Trial)
por: Kolb, Hubert, et al.
Publicado: (2013) -
Patterns of Obesity Development before the Diagnosis of Type 2 Diabetes: The Whitehall II Cohort Study
por: Vistisen, Dorte, et al.
Publicado: (2014)